See more : Dometic Group AB (publ) (DOM.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Personalis, Inc. (PSNL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Personalis, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- The Chiba Kogyo Bank, Ltd. (8337.T) Income Statement Analysis – Financial Results
- Visionary Holdings Inc. (GV) Income Statement Analysis – Financial Results
- Samart Corporation Public Company Limited (SAMART.BK) Income Statement Analysis – Financial Results
- Zijin Mining Group Company Limited (ZIJMY) Income Statement Analysis – Financial Results
- Bafna Pharmaceuticals Limited (BAFNAPHARM.BO) Income Statement Analysis – Financial Results
Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.48M | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M | 9.39M |
| Cost of Revenue | 55.27M | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M | 11.74M |
| Gross Profit | 18.21M | 13.35M | 31.66M | 20.11M | 22.08M | 11.81M | -2.34M |
| Gross Profit Ratio | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Research & Development | 64.78M | 64.91M | 49.31M | 28.57M | 22.42M | 14.30M | 9.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.73M | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M | 9.90M |
| Other Expenses | 13.64M | 61.00K | -42.00K | -24.00K | -1.44M | -33.00K | -227.00K |
| Operating Expenses | 128.14M | 128.88M | 97.01M | 62.26M | 44.50M | 25.58M | 19.82M |
| Cost & Expenses | 183.42M | 180.58M | 150.85M | 120.79M | 87.63M | 51.54M | 31.56M |
| Interest Income | 5.90M | 2.40M | 367.00K | 949.00K | 1.62M | 293.00K | 100.00K |
| Interest Expense | 110.00K | 201.00K | 184.00K | 2.00K | 1.13M | 1.89M | 1.30M |
| Depreciation & Amortization | 11.30M | 12.88M | 8.96M | 7.17M | 5.73M | 3.07M | 1.22M |
| EBITDA | -96.81M | -104.64M | -59.01M | -34.05M | -18.21M | -14.92M | -21.07M |
| EBITDA Ratio | -131.74% | -173.83% | -76.06% | -45.09% | -34.10% | -27.65% | -224.36% |
| Operating Income | -109.94M | -115.53M | -65.35M | -42.15M | -22.42M | -13.77M | -22.16M |
| Operating Income Ratio | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Total Other Income/Expenses | 1.72M | 2.26M | 141.00K | 923.00K | -2.66M | -6.11M | -1.43M |
| Income Before Tax | -108.21M | -113.28M | -65.21M | -41.22M | -25.08M | -19.88M | -23.59M |
| Income Before Tax Ratio | -147.27% | -174.14% | -76.28% | -52.41% | -38.45% | -52.63% | -251.18% |
| Income Tax Expense | 83.00K | 40.00K | 14.00K | 57.00K | 9.00K | 7.00K | 5.00K |
| Net Income | -108.30M | -113.32M | -65.23M | -41.28M | -25.08M | -19.89M | -23.60M |
| Net Income Ratio | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| EPS Diluted | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| Weighted Avg Shares Out | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
| Weighted Avg Shares Out (Dil) | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (PSNL) Q2 2023 Earnings Call Transcript
Personalis Reports Second Quarter 2023 Financial Results
Personalis to Participate at Upcoming Investor Conferences
Personalis to Announce Second Quarter 2023 Financial Results
Personalis to Announce First Quarter 2023 Financial Results
Personalis: Revisiting The Investment Thesis
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Personalis (PSNL) Upgraded to Buy: Here's What You Should Know
Source: https://incomestatements.info
Category: Stock Reports